Mei‐Juan Tu

2.3k total citations · 1 hit paper
64 papers, 1.7k citations indexed

About

Mei‐Juan Tu is a scholar working on Molecular Biology, Cancer Research and Oncology. According to data from OpenAlex, Mei‐Juan Tu has authored 64 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 46 papers in Molecular Biology, 28 papers in Cancer Research and 13 papers in Oncology. Recurrent topics in Mei‐Juan Tu's work include MicroRNA in disease regulation (25 papers), RNA Interference and Gene Delivery (24 papers) and RNA modifications and cancer (19 papers). Mei‐Juan Tu is often cited by papers focused on MicroRNA in disease regulation (25 papers), RNA Interference and Gene Delivery (24 papers) and RNA modifications and cancer (19 papers). Mei‐Juan Tu collaborates with scholars based in United States, China and South Korea. Mei‐Juan Tu's co-authors include Ai‐Ming Yu, Young Hee Choi, Pui Yan Ho, Joseph L. Jilek, Neelu Batra, Su Zeng, Huidi Jiang, Siyuan Sun, Chao Jian and Zhijian Duan and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Scientific Reports.

In The Last Decade

Mei‐Juan Tu

60 papers receiving 1.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

RNA Drugs and RNA Targets for Small Molecules: Principles, Progress, and Challenges

2020 268 citations Ai‐Ming Yu, Mei‐Juan Tu et al. profile →

Peers

Countries citing papers authored by Mei‐Juan Tu

Since Specialization

Citations

This map shows the geographic impact of Mei‐Juan Tu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mei‐Juan Tu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mei‐Juan Tu more than expected).

Fields of papers citing papers by Mei‐Juan Tu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mei‐Juan Tu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mei‐Juan Tu. The network helps show where Mei‐Juan Tu may publish in the future.

Co-authorship network of co-authors of Mei‐Juan Tu

This figure shows the co-authorship network connecting the top 25 collaborators of Mei‐Juan Tu. A scholar is included among the top collaborators of Mei‐Juan Tu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mei‐Juan Tu. Mei‐Juan Tu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Practical Pharmacokinetic–Pharmacodynamic Models in Oncology 2025 ·Pharmaceutics ·(unknown), Mei‐Juan Tu, Ai‐Ming Yu	0
2	Efflux ABC transporters in drug disposition and their posttranscriptional gene regulation by microRNAs 2024 ·Frontiers in Pharmacology ·Yimei Wang, Mei‐Juan Tu, Ai‐Ming Yu	7
3	Novel RNA molecular bioengineering technology efficiently produces functional miRNA agents 2024 ·RNA ·Gavin M. Traber, (unknown), Neelu Batra, Mei‐Juan Tu, Ai‐Ming Yu	6
4	Ruxolitinib Plus Basiliximab Therapy for Steroid-Refractory Acute Graft-Versus-Host Disease in Unrelated Cord Blood Transplantation: A Large-Scale Study 2024 ·Transplantation and Cellular Therapy ·(unknown), Guangyu Sun, Baolin Tang, (unknown), Yaxin Cheng, Mei‐Juan Tu, Xiaoyu Zhu	1
5	Bioengineered RNA Therapy in Patient-Derived Organoids and Xenograft Mouse Models 2022 ·Methods in molecular biology ·Mei‐Juan Tu, (unknown), Gavin M. Traber, Ai‐Ming Yu	2
6	ATR Inhibition in Advanced Urothelial Carcinoma 2022 ·Clinical Genitourinary Cancer ·(unknown), Mei‐Juan Tu, (unknown), Primo N. Lara, Mamta Parikh	4
7	Cytomegalovirus-specific neutralizing antibodies effectively prevent uncontrolled infection after allogeneic hematopoietic stem cell transplantation 2022 ·iScience ·Huiru Wang, Huilan Liu, Zhou Li, Dongyao Wang, Shushu Wang, Qian Liu, (unknown), Mei‐Juan Tu, Zimin Sun, Xiaohu Zheng, Binqing Fu, Baolong Wang, Haiming Wei	2
8	Chimeric Antigen Receptor T Cell Therapy followed by Unrelated Cord Blood Transplantation for the Treatment of Relapsed/Refractory B Cell Acute Lymphoblastic Leukemia in Children and Young Adults: Superior Survival but Relatively High Post-Transplantation Relapse 2021 ·Transplantation and Cellular Therapy ·Guangyu Sun, Baolin Tang, (unknown), (unknown), (unknown), Mei‐Juan Tu, Liangquan Geng, Ping Qiang, (unknown), Lijun Zhu, (unknown), Huilan Liu, Xiaoyu Zhu, Zimin Sun	5
9	Pharmacokinetic and Pharmacodynamic Factors Contribute to Synergism between Let-7c-5p and 5-Fluorouracil in Inhibiting Hepatocellular Carcinoma Cell Viability 2020 ·Drug Metabolism and Disposition ·Joseph L. Jilek, Mei‐Juan Tu, Chao Zhang, Ai‐Ming Yu	19
10	Safety and Efficacy of Ex Vivo Expanded Healthy Donor-Derived Double Negative T Cells for the Treatment of AML Relapsed after Allogeneic Stem Cell Transplantation: A First in-Human Phase I/IIa Clinical Trial 2020 ·Blood ·(unknown), Jongbok Lee, Siqi Cheng, (unknown), Dongyao Wang, Mei‐Juan Tu, (unknown), Liangquan Geng, Mingxia Wang, Ping Qiang, (unknown), Guangyu Sun, (unknown), Huilan Liu, Liming Yang, (unknown), Li Zhang, Xiaoyu Zhu	14
11	A reliable LC-MS/MS method for the quantification of natural amino acids in mouse plasma: Method validation and application to a study on amino acid dynamics during hepatocellular carcinoma progression 2019 ·Journal of Chromatography B ·Zhenzhen Liu, Mei‐Juan Tu, Chao Zhang, Joseph L. Jilek, (unknown), Ai‐Ming Yu	50
12	Bioengineered miR-27b-3p and miR-328-3p modulate drug metabolism and disposition via the regulation of target ADME gene expression 2018 ·Acta Pharmaceutica Sinica B ·(unknown), Ye Tian, Mei‐Juan Tu, Pui Yan Ho, Neelu Batra, Ai‐Ming Yu	56
13	Bioengineered miRNA-1291 prodrug therapy in pancreatic cancer cells and patient-derived xenograft mouse models 2018 ·Cancer Letters ·Mei‐Juan Tu, Pui Yan Ho, (unknown), Chao Jian, (unknown), Edward Kim, Richard J. Bold, Frank J. Gonzalez, Huichang Bi, Ai‐Ming Yu	43
14	Bioengineered NRF2-siRNA Is Effective to Interfere with NRF2 Pathways and Improve Chemosensitivity of Human Cancer Cells 2017 ·Drug Metabolism and Disposition ·Pengcheng Li, Mei‐Juan Tu, Pui Yan Ho, Joseph L. Jilek, Zhijian Duan, (unknown), Aixi Yu, Ai‐Ming Yu	53
15	Genetically engineered pre-microRNA-34a prodrug suppresses orthotopic osteosarcoma xenograft tumor growth via the induction of apoptosis and cell cycle arrest 2016 ·Scientific Reports ·Yong Zhao, Mei‐Juan Tu, (unknown), (unknown), (unknown), Ai‐Ming Yu	40
16	[Establishment of MDCK cell models expressing human MATE1 or co-expressing with human OCT1 or OCT2]. 2015 ·Yaoxue xuebao ·(unknown), (unknown), Liping Li, Mei‐Juan Tu, Hui Zhou, Su Zeng, (unknown)	6
17	MicroRNA Pharmacoepigenetics: Posttranscriptional Regulation Mechanisms behind Variable Drug Disposition and Strategy to Develop More Effective Therapy 2015 ·Drug Metabolism and Disposition ·Ai‐Ming Yu, Ye Tian, Mei‐Juan Tu, Pui Yan Ho, Joseph L. Jilek	64
18	Involvement of organic cation transporter 1 and CYP3A4 in retrorsine-induced toxicity 2014 ·Toxicology ·Mei‐Juan Tu, Liping Li, (unknown), Zhiyuan Ma, Zhongjian Chen, (unknown), (unknown), Hui Zhou, Su Zeng, Huidi Jiang	39
19	Organic cation transporter 1 mediates the uptake of monocrotaline and plays an important role in its hepatotoxicity 2013 ·Toxicology ·Mei‐Juan Tu, Siyuan Sun, Kai Wang, Xueying Peng, (unknown), Liping Li, Su Zeng, Hui Zhou, Huidi Jiang	49
20	The Exposure of Luteolin Is Much Lower than That of Apigenin in Oral Administration of Flos Chrysanthemi Extract to Rats 2011 ·Drug Metabolism and Pharmacokinetics ·Zhongjian Chen, Mei‐Juan Tu, Siyuan Sun, (unknown), Yuqing Wang, (unknown), Liping Li, Su Zeng, Huidi Jiang	45

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact